Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-01-19
DOI
10.3389/fphar.2020.616294
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The relevance of persisters in tuberculosis drug discovery
- (2019) Soma Mandal et al. MICROBIOLOGY-SGM
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way
- (2016) Devyani Deshpande et al. CLINICAL INFECTIOUS DISEASES
- Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps
- (2016) Devyani Deshpande et al. CLINICAL INFECTIOUS DISEASES
- Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests
- (2016) Soumya Swaminathan et al. CLINICAL INFECTIOUS DISEASES
- The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens
- (2015) Dakshina Chilukuri et al. CLINICAL INFECTIOUS DISEASES
- Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes
- (2015) Tawanda Gumbo et al. CLINICAL INFECTIOUS DISEASES
- Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens
- (2015) George G. Zhanel et al. DRUGS
- Streptomycin-Starved Mycobacterium tuberculosis 18b, a Drug Discovery Tool for Latent Tuberculosis
- (2012) Ming Zhang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
- (2012) Shashikant Srivastava et al. CURRENT PHARMACEUTICAL DESIGN
- Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling
- (2011) Shashikant Srivastava et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability
- (2011) Shashikant Srivastava et al. JOURNAL OF INFECTIOUS DISEASES
- Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs
- (2009) T. Gumbo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
- (2009) Clifton E. Barry et al. NATURE REVIEWS MICROBIOLOGY
- Faropenem Medoxomil
- (2007) Jacob P Gettig et al. ANNALS OF PHARMACOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started